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Abstract
Background

Chronic pain is common among people living with cystic fibrosis (CF) and associated with worse clinical
outcomes. Despite this, little is known about how pain is managed and how opioids are used to treat pain. The
purpose of this convergent mixed methods study was to examine self-reported satisfaction and effectiveness of
pain management strategies among a sample of adults with CF who are prescribed opioids.

Methods

We developed an online survey querying 4 domains - demographics, pain characteristics, pain communication,
and management strategies. This was distributed nationally to adults with CF (n=48) via various online
platforms. We obtained quantitative and qualitative responses regarding satisfaction and effectiveness of pain
management. Emerged themes from qualitative data were compared with responses from quantitative survey
domains.

Results

Participants reported high levels of satisfaction and effectiveness with their opioid pain management plans.
However, qualitative themes emerged regarding fears of addiction, experiences of feeling stigmatized by the
healthcare system and ineffectiveness and inefficiency of alternative therapies for adequate pain relief.

Conclusions

Adults with CF reported opioids as an important component of their current pain management plans despite
risks associated with opioid use. CF-specific pain management guideline development is warranted as is further
research exploring pain development.
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1. Introduction
Pain is estimated to affect 42% of adolescents and 77% of adults with cystic fibrosis (CF).1 Sources of pain may
be attributable to identifiable causes such as missed pancreatic enzyme doses or sinus infections, but there is a
subset of individuals who experience debilitating pervasive and chronic pain with no discernable
cause.2 Regardless of cause and location, pain in CF has been associated with decreased health-related quality of
life, depression and increased risk of mortality independent of disease severity, age, and sex.3, 4 There is a
paucity of evidence and lack of clinical guidelines addressing pain management strategies, including what role
opioids have in treating pain in CF. Prior research exploring how individuals with CF manage their pain is sparse.
Opioid drugs have a role in pain management, but evidence of their effectiveness for those with CF has not been
reported and evidence for opioid effectiveness in those with any type of chronic pain not related to cancer is
weak.5 A recent two-year prospective cohort study among persons with chronic non-cancer pain found that at
two years, opioid users had no improvement in effective pain symptom relief. However, at two years they
reported higher satisfaction with treatment, highlighting that satisfaction with opioid pain management does
not necessarily equate with effectiveness of treatment.5 Clinicians cite concerns such as side effects, risk of
abuse, and lack of clear guidelines regarding long-term efficacy for opioids in management of non-cancer
chronic pain.6 These studies support growing evidence questioning the role of opioids for management of
chronic non-cancer pain.

Concerns regarding clear guidelines supporting opioids in chronic non-cancer pain might make multimodal pain
management approaches seem appealing. However, practical barriers to use may limit their actual role in pain
management.6 Both patients and providers describe limitations related to cost, access, and time burden in
utilization of non-pharmacologic pain management approaches.
Despite the clinical implications of chronic pain in CF, little is known about how pain is managed among this
population. Patients with CF and chronic pain have not been represented in previous studies regarding
effectiveness of opioids for chronic non-cancer pain. Given that CF is a unique chronic disease impacting
multiple organs, with varied symptom presentations, it is unclear if previous research regarding effectiveness
and satisfaction with opioids for non-cancer chronic pain management in other populations would apply in
those with CF and chronic pain. Patient perspectives on their experiences are integral to building future pain
management guidelines among this population. With this convergent mixed methods study among a sample of
adults living with CF and using opioids, we aimed to characterize pain experiences, health care utilization, and
examine satisfaction and effectiveness regarding pain management. Furthermore, with a convergent mixed
method study design integrating quantitative and qualitative data, we aimed to gain greater insight into the
experience of pain in CF than would be obtained with quantitative or qualitative approaches alone.7

2. Methods
This study was part of a larger pain management strategies survey distributed in the United States via the Cystic
Fibrosis Foundation Community Voice listserv, various social media sites, and CF care center patient listservs in
Baltimore, Maryland, Chapel Hill, North Carolina, and San Diego, California for 30 days in February, 2018. This
survey collected simultaneous qualitative and quantitative data from the same participants. Participant
responses from those who self-reported the use of opioids were extracted from this larger survey to specifically
explore the effectiveness and satisfaction with pain management plans that contain the use of opioids.
Inclusion criteria included age≥ 14 years old, self-reported diagnosis of CF, self-report of opioid prescription to
treat pain, access to technology such as computer or smart phone, and ability to read/write English. Lung
transplant recipients were excluded. A waiver of written consent was requested in lieu of participation in the
study acting as consent. The study was approved by the [blinded for peer review] Institutional Review Board.
This online cross-sectional survey was developed in collaboration with CF, pain, palliative care, and transplant
experts and included four domains: demographics, pain characteristics, pain communication, and management
strategies (pharmacological, non-pharmacological, complementary/alternative modalities). Participants
completed 29 multiple choice and Likert scale questions as well as qualitative narrative responses. Likert-scale
responses were organized to present negative responses first to minimize risk of bias. Participants were
encouraged to elaborate on perceptions and experiences regarding pain characteristics, management strategies,
and healthcare utilization via open-ended qualitative questions.
Demographic information included: age, gender, marital status, education, work status, race/ethnicity,
insurance status, and baseline percent predicted forced expiratory volume in one second (FEV1%) range.
The pain characteristics domain used components of the Brief Pain Inventory, a validated measure used
extensively in pain research to explain pain frequency description, and effect on day-to-day life and mood.8 This
domain also included questions regarding formal chronic pain diagnoses and CF-related pain beliefs.
The communication domain explored if and how participants discussed pain with their healthcare team. Positive
responses prompted a 5-point Likert probe on satisfaction of support received from those conversations.
Respondents provided qualitative responses regarding how they feel pain should be approached as part of their
healthcare plan.

The management domain explored over-the-counter medication use (e.g. acetaminophen, ibuprofen, lidocaine
patches, etc.), prescription medications (e.g. opioids, anti-depressants, steroids, etc.), non-traditional medicines
(e.g. herbal supplements, essential oils, marijuana if legal in state of residence, etc.), and therapies (e.g. heat,
ice, massage, guided imagery, etc.) specific for treatment of pain. Positive responses prompted a 5-point Likert
probe on satisfaction, effectiveness and how they learned about pain management therapy/medication.
Descriptive statistics including frequencies, median, mode, and range were used to describe the study sample
and characterize the Likert-scale responses. Qualitative responses underwent conventional content analysis.
Conventional content analysis is a qualitative data analysis approach in which researchers determine the
presence of certain words, themes, or concepts within some given qualitative data. We used content analysis in
our study to analyze the presence, meanings and relationships of such certain words, themes, or
concepts.9 Responses were read independently by SA and JZ to allow for general impressions of content to
develop into categories and preliminary codes. Discrepancies were reconciled through team consensus for
emergent codes. Results were mixed by comparing emerged themes with responses from each survey domain.
Results were anonymized and reported as self-identified gender and age in years. Peer review of the analysis
was performed by a mixed methods expert to ensure trustworthiness.
Mixing in this convergent design occurred during data collection, analysis, and interpretation of results.
Quantitative and qualitative data were collected concurrently from the same participants. Themes from
qualitative data were compared with responses from quantitative survey domains. Results of quantitative and
qualitative data were integrated in joint data displays (Tables 2 and 3).7

3. Results
The survey study included 274 participants, 101 (37.2%) reported being prescribed medications for pain. Of
those prescribed pain medication, 48 or 17.5% of original sample reported being prescribed opioids for pain.
Due to our study's focus on opioid pain management, our analytic sample was limited to those participants
(N=48) (Table 1). The median age of the sample was 36 years with a range of 18-72 years. Most of the sample
identified as female (n=41, 85%), White (n=44, 92%), and had completed at least some college (n=39, 81%). Half
of the sample were married or in a partnership. Over half (n=25, 52%) were unable to work or attend school due
to health problems. Nearly half (n=23, 48%) reported FEV1% predicted <50% and 23% and were undergoing
transplant evaluation.
Table 1. Demographic Characteristics of adult CF patients receiving opioid pain medication (N=48)
Mean Age (SD)
38.4 (12.8)
Gender
Female
85%
Marital Status
Single
33%
Married/Partnered
50%
Divorced
13%
Education
High School
10%
Some College
35%
College Gradate
46%
Master's Degree
8%
Race/Ethnicity
White
94%
Hispanic
4%

Asian
Insurance
Private
Medicare/Medicaid
Baseline Lung Function
Greater than 80%
70-79%
50-69%
Less than 50%
Undergoing lung transplant evaluation
Chronic Pain Diagnosis

2%
44%
56%
8%
19%
21%
50%
23%
58%

3.1. Pain characteristics

The majority of participants (n=34, 70%) believed their pain was CF related. Top five pain locations reported
were chest (n=36, 75%), joints (n=36, 75%), head (n=33, 68%), sinus (n=31, 65%), and abdomen (n=30,
63%). Thirty-three participants (68%) reported pain affected their daily life very often or always with 86% of the
overall sample reporting experiencing pain > 4 times per week. In addition, pain was reported to affect mood
moderately to a great deal by nearly three-quarters of participants (n=35, 73%) (Fig. 1).

Fig. 1. Pain characteristics among adults with CF utilizing opioid pain management (N=48)

3.2. Opioid pain management and experiences

The most prescribed opioids reported in the sample were tramadol (n=21, 43%), oxycodone (n=21,
43%), and hydrocodone (n=14, 29%), with less than 5% of participants reporting methadone, fentanyl, or
morphine prescriptions (Table 2). Largely, participants were satisfied or very satisfied with their use of opioids.
However, satisfaction varied across types of opioid medications. 75% of participants stated they were satisfied
or very satisfied with oxycodone compared to only 43% with tramadol. When analyzing overarching themes of

effectiveness and satisfaction, qualitative responses revealed several subthemes including delayed use for pain,
tolerance concerns, fear of addiction, and opioid side effects.

Table 2. Effectiveness, Satisfaction, and Experiences of Opioid Pain Management
Effectiveness and
Opioid
Satisfaction of drug Active
for pain
Ingredient
management
Effectiveness
Tramadol
Oxycodone (N=21) Hydrocodone (N=14) Methadone (N=2) Fentanyl
(N=21)
(N=2)
My pain goes away
29%
55%
42%
0%
0%
all of the time when
I use this medication

Qualitative themes

Morphine
(N=1)
100%

My pain goes away
some of the time
when I use this
medication
My pain doesn't
change when I use
this medication
I can't tell if my pain
changes or not
when I use this
medication
My pain gets worse
when I use this
medication
Satisfaction with
Use
Very dissatisfied

24%

40%

58%

0%

100%

0%

33%

5%

0%

100%

0%

0%

14%

0%

0%

0%

0%

0%

0%

0%

0%

0%

0%

0%

10%

0%

0%

0%

0%

0%

Dissatisfied
Neither satisfied or
dissatisfied
Satisfied
Very Satisfied

24%
24%

15%
10%

15%
23%

0%
0%

0%
50%

0%
0%

19%
24%

35%
40%

46%
15%

50%
50%

50%
0%

0%
100%

Effectiveness
impacted by:
Tolerance Concerns
Delayed use for pain
(opioids as a last
resort)

Satisfaction with
Use Impacted by:
Opioid side effects
Fear of developing
opioid addiction

3.2.1. Effectiveness
3.2.1.1. Delayed use for pain (opioids as a last resort)
Participants often described pain as unmanageable by other modalities or non-opioid medications and utilized
opioids as a last resort when other methods failed to provide adequate relief. Most participants approached
opioid use cautiously and elected to use opioids only when other options were exhausted.
“I do not take this (tramadol) all the time, I only take this when the pain is debilitating and makes me cry
or I cannot move from the stiffness of my joints causing me severe agony. I do not want to become
addicted.” (Female, 29)
3.2.1.2. Tolerance concerns
Many viewed opioid use as long term and related pain management to their chronic disease process. Pain
management was ineffective for some when tolerance was reached and dosing schedules not adjusted
accordingly. Participants expressed fear of needing escalating doses over time.
“..And you need more and more and more, and I'm not even 30. How much am I going to need if I live to
50? .. But what else am I supposed to do?” (Female, 27)

3.2.2. Satisfaction
3.2.2.1. Fear of developing opioid addiction
Participants expressed concerns over developing addiction. While opioids were effective for pain control,
participants expressed knowledge about risks of abuse and were balancing these concerns with pain
management.
“At times it works and at times it doesn't. I am so afraid of being addicted to them that it keeps me from
taking them when I need them and I just bear the pain.” (Female, 29)
3.2.2.2. Opioid Side Effects
Most participants described opioids as effective in managing pain. However, they reported side effects related
to opioid use. Participants weighed the benefits of pain management with undesirable side effects
including negative effects on their GI system (i.e., constipation, nausea, liver damage)
“The oxycodone often works but it effects my GI system negatively. Would love to see an alternative.”
(Female, 49)
Participants also reported negative mental effects including lethargy and mood changes. …"it takes away my
ability to participate in life because it makes sleepy or loopy.” (Female, 35)

3.3. Multimodal pain management

Most participants reported using a multi-modal approach to pain management incorporating non-opioid
medications and/or non-pharmacological therapies including physical therapy, acupuncture, and/or procedures
such as nerve blocks (Table 3). However, when asked to further explain experiences with these therapies,
themes and subthemes emerged around effectiveness (suboptimal pain control, contraindication to use) and
satisfaction (financial barriers, treatment time requirements)

Table 3. Effectiveness, Satisfaction, and Experiences of Multimodal Pain Management Strategies
NonPain selfopioid
managem
pain
ent
medicati
ons
Effectiven NSAIDS
Antidepress Corticoster Acetaminop Hot
Probiot Ice
ess and
(N=30)
ants (N=27) oids (N=25) hen (N=24) Packs/
ics
packs/c
satisfactio
Heat
(N=12) old
n of
Therapy
therapy
strategy
(N=26)
(n=14)
for pain
managem
ent
Effectiven
ess: When
I use this
strategy,
my pain..
Goes
3%
0%
6%
0%
0%
0%
0%
away all
of the
time
Goes
away
some of
the time
Doesn't
change
I can't tell
if it
changes
Gets
worse

Pain
thera
py
servic
es
Physi
cal
thera
py
(N=12
)

Chiroprac
tor
(N=11)

Acupunct
ure (N=5)

Qualitative
themes

Effectivenes
s impacted
by:
8%

0%

0%

73%

100%

29%

58%

85%

42%

79%

67%

91%

20%

17%

0%

41%

25%

15%

8%

14%

8%%

0%

40%

7%

0%

24%

17%

0%

50%

0%

0%

9%

40%

0%

0%

0%

0%

0%

0%

7%

17%

0%

0%

Suboptimal
control
severe pain
Contraindica
tion to use

Satisfactio
n with
Use
Very
dissatisfie
d

0%

0%

0%

4%

0%

8%

7%

8%

0%

8%

Dissatisfie
d
Neither
Satisfied
or
dissatisfie
d
Satisfied
Very
Satisfied

30%%

0%

6%

25%

0%

0%

14%

0%

9%

0%

40%

0%

47%

58%

42%

67%

50%

33%

9%

67%

23%
7%

50%
50%

47%
0%

13%
0%

50%
8%

17%
8%

29%
0%

58%
0%

63%
18%

17%
8%

Satisfaction
with Use
Impacted
by:
Financial
Barriers
Treatment
time
requirement
s

3.3.1 Effectiveness
3.3.1.1. Contraindications to use
A key sub-theme identified regarding non-opioid pain medications was that use was often contraindicated
by comorbidities. End-organ damage i.e., impaired renal function, liver disease, and risk for hemoptysis limited
utilization of these drugs.
“..can't take NSAIDs due to kidney function. But sometimes out of desperation I take a Celebrex because
it helps so much.” (Female, 63)
3.3.1.2. Suboptimal control of severe pain
Non-pharmacological methods were described as having limited effect on participants’ pain, including
ineffectiveness for severe pain. These methods were seen as having low efficacy, being difficult to access, and
serving only an adjunctive to pain management.
“Just like exercise, this helps 'loosen up' my muscles a bit sometimes. But, with more moderate to severe
pain, yoga is not a complete solution. Also, hard to start when you're really in pain.” (Female, 35)

3.3.2. Satisfaction
3.3.2.1. Financial barriers
Treatment options such as physical therapy, acupuncture, and CBD oil were often minimally or not covered by
insurance. Participants often limited, avoided, or modified recommended use of multimodal treatments in
response to prohibitive out-of-pocket expenses.
“Regarding physical therapy: The main disadvantage to these are the extremely high cost. … one session
costs a lot and to get the relief I need I would need to go 2-3 times per week. There is no way I could
afford that. However, I do benefit from it when I can afford to get a couple here and there.” (Male, 28)
3.3.2.2. Treatment time requirements
In addition to expenses, participants reported time commitment hindered ability to participate in treatment
such as physical therapy.
“I have done several rounds of physical therapy with mixed results. The traditional PT Schedule did not
really work for me, rather the timeline was greatly extended to get results.” (Male, 33)

3.4. Discussing pain management with CF health care providers

Nearly half (42%) of participants were satisfied or very satisfied with their current outpatient pain management.
However, participants reported feeling uncomfortable addressing pain with CF teams, with sixteen (33%)
reporting not discussing pain during clinic visits.
1. Several subthemes regarding satisfaction emerged including fears of being stigmatized, dismissal of pain
experiences (vs. feeling supported) and having a champion.

3.4.1 Satisfaction
3.4.1.1. Fears of being stigmatized
Participants perceived stigma associated with the type of people who use opioids – abusers, addicts – and
shared fears that care teams may perceive them to be addicted and drug seeking if they request another
prescription or changes to their regimen. Feelings of being torn between treating pain effectively or stopping
opioids to improve care team perceptions were expressed.
“We are scared to tell the doctors we're in pain and need to do something about it because of the fear of
being labeled a pill seeker. So, it becomes a very bottled-up mess that I truly believe is under reported

and definitely under treated. Which is a major shame because when properly relieved of even just some
of the pain makes life so much more enjoyable.” (Male, 28)
3.4.2.1. Dismissal of pain experiences (vs. feeling supported)
Many participants shared feeling that their pain experiences were dismissed or minimized by care teams, often
being told that pain is part of having CF, or having other issues like lung health take priority to pain. Others
expressed frustration that their sources of pain were poorly understood and felt care teams were not helping
them to understand their pain, leading to fears that their experiences were being minimized.
“It's a constant thing I live with, and it feels like it's expected with having CF and therefore not seen as an
urgent concern. I've had a doctor tell me,’ it's just a part of the disease progression,’ and I don't want to
accept that. There should be more done to address this in every visit, or refer me to a pain clinic to work
on it.” (Female, 36)
3.4.2.2. Having a champion
While there were frustrations regarding pain management experiences, there was also an experience of feeling
supported by someone within care teams among participants. Some felt they had one provider either from
within or outside their CF team who listened to them and worked hard to find ways to help them
cope. Participants expressed thanks to these individuals for being able to find relief. They also shared how
much this support in having an effective pain management plan improved their quality of life.
“It is a constant daily battle that I fight with pain. It seems to get worse the older I get. To be honest the
pain aspect is my biggest complaint. It makes all the other CF stuff easy. But I am at a new pain clinic
with doctors very familiar with CF pain who prescribe me pain medication along with weekly
massage, chiropractor, and pulmonary rehab. It has gotten much more under control and my quality of
life is so much better.” (Male, 28)

4. Discussion
Through quantitative survey data and rich in-depth patient-reported experiences, our study provides valuable
insight into pain management among people with CF. Results of quantitative data showed that satisfaction with
and effectiveness of pain management plans was mostly positive. However, when exploring these findings,
qualitative themes emerged providing nuanced information regarding not just negative effects of opioids such
as fears of addiction, but also experiences of feeling stigmatized by the healthcare system and ineffectiveness
and inefficiency of alternative therapies. These findings highlight the pain experience from the patient's
perspective, which in turn, has important implications for the CF care teams.

4.1. Challenges in addressing pain in the CF clinic

Despite most reporting satisfaction with pain management, many participants desired more integrated care and
better understanding of the relationship between chronic pain and CF. The overwhelming majority of
participants believed their pain was directly related to CF, and, as in other studies, reported a wide range of
locations and types of pain. In addition, many voiced frustrations with not knowing, nor understanding
contributory mechanisms to their pain. CF causes many painful disease processes such as sinus disease and GI
pain that are often easily identified and improved by treating the underlying cause. However, persistent,
generalized pain or pain not linked to a specific event can be difficult to understand and, likewise, treat.10 Side
effects from antibiotics and inflammation as part of the CF disease process are likely contributors, but little is
known about other characteristics of both CF and psychosocial contributors to chronic pain development3. A
better understanding of these contributory mechanisms of pain development in CF is needed.

Only 58% of this sample reported having a chronic pain diagnosis, possibly reflecting that, although care
providers are treating pain, many individuals are missing formal pain diagnoses to support use of opioids as their
primary means of pain control. It is possible that these participants were therefore receiving episodic
management of pain versus comprehensive pain management approaches associated with a more formal
chronic pain diagnosis. It is also possible that absence of a chronic pain associated diagnostic code in the medical
record could prohibit or limit insurance reimbursement to alternative therapies such as acupuncture and
manipulative therapies such as physical therapy and chiropractic. Secondary chronic pain – chronic pain that is a
symptom of an underlying condition – is a relatively new diagnostic distinction from primary chronic pain, but
could be useful in CF, as it has been for others who experience pain as a result of life-limiting chronic
disease.11 Improvements in how pain is understood as well as normalizing pain in CF via use of the secondary
chronic pain diagnosis may improve both satisfaction and effectiveness of pain management plans.
Participants discussed fears of stigmatization as an addict or pill seeker, highlighting a need for belief and
validation of their pain experience by CF teams and other providers. This fear of stigmatization has been
reported in non-CF chronic pain populations and the CF population alike12. Whether driven by actual disbelief of
an individual's pain, or by the individual's anticipation that their healthcare team will not believe them, fear of
stigmatization may contribute to hesitancy to talk about pain. As communication is key to trust and
understanding in the therapeutic relationship, this hesitancy is particularly concerning. Therefore, CF health care
providers should ask about pain at each encounter versus waiting for patient-initiated pain conversations.

4.2. Barriers to effective pain control

Recent updates in chronic pain management recommends a multi-modal approach to address not just physical,
but mental and psychological factors that contribute to how pain is processed and experienced.13 Participants
were familiar with and reported using a multitude of non-pharmacological and non-opioid pharmacologic
strategies to help with pain control to varying degrees of efficacy and satisfaction in addition to their use of
opioids. Suboptimal pain control, contraindications to use, availability, costs, and the time commitments
required by many modalities, however, limited their contribution to effective pain management plans, which is
consistent with findings from non-CF chronic pain studies. In addition, participants reported limiting their use of
opioids sparingly and as a last resort, citing fears of addiction and increased drug tolerance with resultant
decreases in medication. Participants’ wariness regarding opioids is supported by a growing body of evidence
supporting that risks and ineffectiveness of opioids far outweighs the benefits in non-cancer chronic pain. A
recent comparative effectiveness systematic review concluded while opioids offer beneficial effects on noncancer chronic pain compared to placebo, they do not appear to be superior to non-opioid therapies.14
Supporting these findings, this sample largely reported their current opioid pain management plan to be
effective, but also reported that alternative medications such as non-steroidal anti-inflammatories
and acetaminophen were just as effective, if not more, than opioids. Participants described being cautioned
away from non-opioid medications related to liver and/or kidney insufficiencies. While it is recommended that
those with both renal and liver disease avoid NSAIDS, current clinical guidelines support use of acetaminophen
for mild to moderate pain in both these populations[15], [16], [17], suggesting that removal of acetaminophen
for pain management in those with CF-related liver disease or impaired renal function may be overly cautious. It
is important to note, however, that no recent studies examining effects of acetaminophen on organ function
have been conducted in those with CF18, so heightened surveillance of liver function, especially given the impact
of new highly effective modulator therapies (HEMT) on the liver, may be warranted in chronic acetaminophen
use.

4.3. Important considerations in individuals receiving opioids

A recent study by Yaoli et al. (2021) surveying CF providers about attitudes of pain and opioid prescription
practices found that greater than 50% of providers of adults with CF are uncomfortable or only slightly
comfortable prescribing opioids. Addiction and the possibility of patients being ineligible for lung
transplantation were reported as barriers to their use.19 However, for some CF patients with chronic pain,
opioids are a critical component of their plan of care. In these instances, CF providers must actively engage with
patients to monitor side effects, consult with specialists, and tailor an individualized prescribing plan for each
patient as suggested in Table 4. Consistent with the CDC recommendations for clinicians regarding prescribing
opioids for chronic pain20, the use of opioids for those with CF and pain should be approached in a step-wise
fashion that incorporates patient-driven considerations that evaluate and focused on a safe and effective
management plan.
Table 4. Suggested approach to a patient-driven pain management plan that incorporates opioids
Evaluation
Management
Evaluate characteristics and cause(s) of
Determine eligibility for non-pharmacologic and non-opioid
pain, recognizing that a discernable cause pharmacologic options; consult with pain specialist, palliative
may not be apparent
care specialist, and/or pharmacologist as appropriate
Review the effects of pain on daily life
Set goals for pain management and provide education on
and functional status
potential adverse effects
Evaluate for contributions related to
Communication with and referral to other specialists as
depression, anxiety, and/or dyspnea
appropriate
Review efficacy, adverse effects, and
Outline follow-up and safety monitoring plan; provide access to
barriers to previous and current
resources such as social support as needed
treatments
Address perceived stigma or other
Review satisfaction and adverse effects regularly; consider
specific concerns related to pain and/or
tapering doses as appropriate
related treatments

5. Limitations
This study should be considered in light of several limitations. The sample size in this study is small (N=48) with
missing quantitative data points on several survey items. The quantitative data is cross-sectional therefore we
were able to identify associations versus causal relationships. This limitation is mitigated by mixed method
design and inclusion of qualitative data. Female participants were over-represented and half of the sample had
lung function representative of severe disease progression with many in the process of undergoing evaluations
for a lung transplant. Though previous studies have reported no association between pain, sex, and/or lung
function, it is possible that responses to pain management treatments are experienced differently by those
groups not represented by this survey study. In addition, our study did not include those who have
undergone lung transplantation. This population may also have unique pain considerations not represented by
tis study. Further studies with larger sample sizes that incorporate a more equal representation of men and
equal distribution of disease severity is necessary for generalizability to the broader CF population. Furthermore,
our study did not assess participants for mental health co-morbidities such as depression, which is often linked
to how pain is experienced and can be a risk consideration when adding opioids to pain management plans.
Future studies exploring this relationship are warranted. This study pre-dated the wide-spread use of HEMT. It is
possible that use of these medications may have an impact on pain and thus, how it is managed. A
longitudinal cohort study is currently underway to explore the impact of HEMT on pain in adults with CF.

6. Conclusion
In our study, satisfaction with opioids for pain relief in adults with CF was influenced by many factors including
recognition of negative risks associated with opioids and the importance in being open to communicate pain to
healthcare providers. Effectiveness of pain management plans that incorporate opioids was influenced by lack of
non-opioid medications and barriers to multimodal therapies. This study highlights the need for guideline-driven
practice standards, including the role of opioid medications for chronic pain management in CF.
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